 |
 |
|
 |
 |
 |
北京亚太肝病诊疗技术联盟
电话：010-53383907
邮箱：fanyatongze516@163.com
网址：www.apald.org
地址：东园文化创意广场F座2层216
|
 |
 |
|
 |
|
 |
 |
 |
 |
| |
|
发布时间：2022/7/16 浏览次数：651 |
|
摘要：
|
|
摘要：基础研究证据提示黄芩苷可能通过多种机制对抑制肝炎病毒复制、减轻肝脏 脂肪变、减轻肝纤维化并抑制肝癌提供辅助治疗作用。临床研究也初步显示了慢性 乙型肝炎患者在抗病毒治疗基础上联合黄芩苷胶囊治疗有助于降低HBV DNA及HBV pgRNA水平，对提高HBeAg阴转率及ALT复常率有帮助。专家委员会基于现有证据建 议考虑黄芩苷胶囊对慢性乙型肝炎患者的辅助治疗用途，同时建议进一步加强黄芩苷 胶囊用于乙型肝炎、代谢相关脂肪性肝病及酒精性肝病等各型肝脏疾病治疗的临床研 究，明确黄芩苷胶囊在肝脏疾病中的治疗价值。
|
|
Abstract: Basic research showed Baicalin may inhibit hepatitis virus replication, attenuate liver steatosis and fibrosis, and inhibit hepatocellular carcinoma through multiple mechanisms. Clinical studies showed adjuvant therapy with Baicalin may further inhibit HBV DNA and HBV pgRNA, improve HBeAg negativity and ALT normalization in chronic hepatitis B patients treated with antiviral agents. The expert commission recommend the use of Baicalin as adjuvant therapy for chronic hepatitis B based on current evidence. Further studies are also suggested to verify the adjuvant effect of Baicalin for hepatitis B, hepatitis C, metabolic associated fatty liver diseases and alcoholic liver diseases.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|
|
| |
|
 |
 |
|
